Non-Small Cell Lung Cancer (NSCLC) Clinical Trials

• Voluntarily participate in the study and signed the Informed Consent Form (ICF).

• Be willing to and able to participate in the trial and comply with the follow up procedures;

• Male or female, aged 18-75 years.

• Expected survival ≥ 3 months.

• ECOG PS score 0 or 1.

• Histopathologically or cytologically confirmed locally advanced or metastatic NSCLC not eligible for curative treatment.

• No prior systemic anti-tumor treatment for advanced or metastatic squamous NSCLC.

• Sufficient cardiac, bone marrow, hepatic, renal, and coagulation function.

• Female participants must be postmenopausal, surgically sterilized, or of childbearing potential with a negative blood pregnancy test within 7 days before the first dose. Female participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate oocytes or breastfeed during this period. Male participants must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must not donate sperm during this period.

⁃ At least one measurable lesion outside of the brain according to the RECIST v1.1 criteria.

⁃ A PD-L1 expression test report that meets the requirements must be provided before enrollment.